Status:

UNKNOWN

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer

Lead Sponsor:

Peking University Cancer Hospital & Institute

Collaborating Sponsors:

Geneplus-Beijing Co. Ltd.

Conditions:

NSCLC

Eligibility:

All Genders

18-80 years

Brief Summary

Stratification of postoperative ctDNA status can effectively assess the risk of recurrence in patients. In addition, the multi-node dynamic monitoring of ctDNA is more effective in predicting the recu...

Detailed Description

In this prospective study, 65 patients with potentially operable non-small cell lung cancer without driving gene EGFR/ALK mutation in stage III were enrolled in this prospective study. peripheral bloo...

Eligibility Criteria

Inclusion

  • Capable of giving signed informed consent, age ≥ 18 and ≤ 80.
  • patients with stage Ⅲ non-small cell lung cancer confirmed by histology or cytology have potential surgical opportunities.
  • No driving gene EGFR/ALK mutation.
  • PS = 0-1.
  • the treatment process cooperated with the provision of clinicopathological and imaging data needed in the research process, followed up and collected the blood of the clinical efficacy evaluation nodes, and agreed to use the test data for follow-up research and product development.

Exclusion

  • patients suffering from other malignant tumors.
  • patients change the treatment regimen before receiving the specified treatment or before the disease progresses.
  • Patients could not cooperate with the study for follow-up according to the defined clinical follow-up period;
  • Patients were unable to accept or provide imaging and other designated therapeutic evaluation means.

Key Trial Info

Start Date :

November 25 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2025

Estimated Enrollment :

65 Patients enrolled

Trial Details

Trial ID

NCT06081777

Start Date

November 25 2022

End Date

June 1 2025

Last Update

October 13 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Yuyan Wang

Beijing, China, 100142

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer | DecenTrialz